Addressing Drug Shortages

According to the University of Utah Drug Information Service, there were 211 reported drug shortages for calendar year 2010. In 2011, the number of drug shortages increased to nearly 300. Of these, nearly one-third were for the treatment of cancer or cancer symptoms. The shortage of some cancer drugs is not just affecting patients currently undergoing treatment, but it is also having a significant negative impact on current and future cancer clinical trials. These shortages have resulted in important cancer clinical trials being delayed, suspended and/or halting the accrual of new patients.

NCCR is committed to working with bipartisan Members of Congress to address this urgent issue. As an initial means to address drug shortages, NCCR supports H.R. 2245 and S. 296, the “Preserving Access to Life-Saving Medications Act of 2011.” This legislation would to require the manufacturer of a prescription drug marketed in interstate commerce to notify the Secretary of Health and Human Services (HHS) of a discontinuance or interruption in the manufacture of the drug.

NCCR Letter

NCCR Testimony_HELP_Committee_Rx_shortages

NCCR Testimony SFC Rx shortage hearing

NCCR responds to Food and Drug Administration Drug Shortages

NCCR Comment Letter